Navigation Links
15-Minute Data From Phase 3 Study of Avanafil Featured as a Late Breaking Abstract at SMSNA Annual Meeting
Date:11/14/2011

MOUNTAIN VIEW, Calif., Nov. 14, 2011 /PRNewswire/ -- VIVUS, Inc. (NASDAQ: VVUS) today announced that new analyses from TA-314, a phase 3 long-term safety and efficacy study of the investigational drug avanafil for the treatment of erectile dysfunction (ED), was presented over the weekend at the 2011 Sexual Medicine Society of North America (SMSNA) Meeting in Las Vegas, NV.  Andrew R. McCullough, MD, Professor of Surgery/Urology at Albany Medical College, presented the analysis of results from the study that showed that avanafil was effective in as early as 15 minutes after dosing when analyzed both by subject and attempt.  Of the subjects attempting intercourse </=15 minutes of dosing, 83% had successful intercourse.  Additionally, eighty percent (80%) of all study-wide sexual attempts made within 15 minutes of dosing were successful.

The study entitled, "An Open-label, Long-term Evaluation of the Safety and Efficacy of Avanafil in Men with Erectile Dysfunction" was presented during the Late Breaking Trials Session on November 12, 2011.  Dr. McCullough concluded that based on the results of the study, this onset of action suggests that avanafil, if approved, is potentially well-suited for on-demand treatment in men with mild to severe ED.

About AvanafilAvanafil is an investigational oral drug being developed for the treatment of erectile dysfunction.  Avanafil is a highly selective phosphodiesterase type 5 (PDE5) inhibitor licensed from Mitsubishi Tanabe Pharma Corporation.  VIVUS owns worldwide development and commercial rights to avanafil for the treatment of sexual dysfunction, with the exception of certain Asian Pacific Rim countries.

About VIVUSVIVUS is a biopharmaceutical company developing therapies to address obesity, sleep apnea, diabetes and male sexual health.  The company's lead investigational product in c
'/>"/>

SOURCE VIVUS, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Merrimack Pharmaceuticals Initiates Enrollment in a Phase 1 Study of MM-121, an ErbB3 Antagonist
2. BioMS Medical announces positive interim analysis on phase III trial of dirucotide (MBP8298) for multiple sclerosis
3. Dendreon Initiates Second of Two New Phase 2 Trials of PROVENGE for Prostate Cancer
4. Palatin Technologies, Inc. Reports Positive Results of Phase 2a Clinical Study with PL-3994 for the Treatment of Heart Failure
5. Logical Therapeutics Inc. Announces Results of Phase 1b Clinical Study of its Naproxen Prodrug
6. PTC124 Shows Promising Activity in Cystic Fibrosis; Phase 2 Proof-of-Concept Data Published in the Lancet
7. NovaRx Initiates Pivotal Phase III Clinical Trial in Lung Cancer Patients
8. Michigan Innovation Equipment Depot Launches Next Phase of Distribution
9. Phase 1b/2a Program Commences for RVX-208
10. Chiltern Early Phase: Fully Integrated and Business Ready
11. Oncolytics Biotech Inc. Announces U.S. Phase 2 Combination Clinical Trial for Non-Small Cell Lung Cancer Patients with K-RAS or EGFR-Activated Tumours
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/13/2014)... (PRWEB) December 12, 2014 Trend lines ... in overall global economic growth, Eugene Arthurs, CEO of ... , said in a featured talk at OPTIC (Optics ... at the National Chung Hsing University in Taichung. , ... integrated into future energy supplies and soon to hit ...
(Date:12/13/2014)... 2014 QuickSTAT is making significant investments ... Chain capabilities, and is delighted to announce the opening ... serve Life Science clients in the region. , QuickSTAT ... warehouse, will provide 24/7 transportation and logistics services, as ... patient-clinical specimens, API, following IATA rules and EU GDP ...
(Date:12/13/2014)... 12, 2014  Vaccinex Inc., a clinical-stage ... development of therapeutic monoclonal antibodies to treat ... of a manuscript entitled "SEMA4D compromises blood–brain ... neurodegenerative disease" in the January 2015 issue ... publication highlights an important role for antibodies ...
(Date:12/12/2014)... (PRWEB) December 11, 2014 Graphite Metallizing ... materials for pumps and process equipment, has appointed Kirk ... States and Ontario, Canada. Staller holds a B.S. degree ... in the industrial market place, much of it with ... out of his Michigan office. , “We are ...
Breaking Biology Technology:Photonics Continues Upward Trends Despite Challenges in the Global Economy, Notes SPIE CEO 2Photonics Continues Upward Trends Despite Challenges in the Global Economy, Notes SPIE CEO 3Photonics Continues Upward Trends Despite Challenges in the Global Economy, Notes SPIE CEO 4Photonics Continues Upward Trends Despite Challenges in the Global Economy, Notes SPIE CEO 5Quick Opens Office in France to Serve Life Science Community In France and Neighboring French-Speaking Countries 2Vaccinex announces publication of preclinical studies with an anti-SEMA4D antibody in animal models of neuroinflammatory and demyelinating disease 2Kirk Staller Joins Graphite Metallizing Corporation 2
... Total Site Solutions,(TSS), a Fortress International Group Company ... the planning, design and development of,mission-critical facilities today ... industry has awarded them the construction,management phase of ... performed technology consulting services to analyze,short term and ...
... Allos,Therapeutics, Inc. (Nasdaq: ALTH ), a biopharmaceutical ... molecule therapeutics for,the treatment of cancer, today announced ... a corporate overview at the 2007 UBS Global ... presentation will take place at 3:30 p.m. (Eastern) ...
... leader in,the rapidly evolving field of cancer molecular diagnostics, ... Lindenbergh as Chairman of its,Supervisory Board. Hessel Lindenbergh ... ING,Group N.V.. Currently, Mr. Lindenbergh is chairman of the ... the Royal Numico, Petroplus,International and Gamma Holding. Mr. Lindenbergh ...
Cached Biology Technology:Total Site Solutions Selected to Provide Construction Management Services for Existing Pharmaceutical and Biotech Customer for Data Center Expansion Project 2Total Site Solutions Selected to Provide Construction Management Services for Existing Pharmaceutical and Biotech Customer for Data Center Expansion Project 3Allos Therapeutics to Present at the 2007 UBS Global Life Sciences Conference 2Agendia BV Appoints Mr. Hessel Lindenbergh as Chairman of its Supervisory Board 2
(Date:11/21/2014)... MOUNTAIN VIEW, Calif. , Nov. 20, 2014 /PRNewswire/ ... for higher driver efficiency are piloting the North American ... the number of accidents growing, gesture recognition systems that ... will make a mark in the industry. ... of the Automotive Gesture Recognition Market in ...
(Date:11/18/2014)... , Nov. 17, 2014 The Parenteral Drug ... U.S. regulatory agencies will speak and at least seven more ... Conference at the Omni Shoreham Hotel in Washington ... once again to have significant support from the regulatory agencies ... Europe in our effort to help advance ...
(Date:11/10/2014)... appearing on U.S. store shelves in early 2010, and ... The small packets can be tossed into a washing ... or powder. The convenience, though, has come with risks ... at Nationwide Children,s Hospital found that from 2012 through ... children younger than 6 years of age swallowing, inhaling, ...
Breaking Biology News(10 mins):Gesture Recognition Intensifies with the Rise of In-car Smartphone Integration, Says Frost & Sullivan 2Gesture Recognition Intensifies with the Rise of In-car Smartphone Integration, Says Frost & Sullivan 3Gesture Recognition Intensifies with the Rise of In-car Smartphone Integration, Says Frost & Sullivan 4FDA's Janet Woodcock, EMA's Emer Cooke Headline PDA Quality Metrics Conference 2Study finds laundry detergent pods, serious poisoning risk for children 2
... a study has compared water quality trends in forested streams ... or land cover changes. The study, which draws on ... states and Puerto Rico, underscores the value of long-term data ... in streams and rivers. It is published in the current ...
... sick with colon cancer, received a blood transfusion. Then, unexpectedly, ... on her case, the French medical journal Revue D,Hmatologie identified ... it turns out, Mrs. Vel had developed a potent antibody ... of most people in the worldbut not found on her ...
... Philanthropist, businessman and community leader John Moores has given ... fund the development of a new field test for ... tens of millions of people in Africa, Latin America ... John,s generosity and foresight," said Michael A. Marletta, president ...
Cached Biology News:Study explores long-term water quality trends in near-pristine streams 2Baffling blood problem explained 2Baffling blood problem explained 3John Moores gives $2 million to Scripps Research to develop river blindness field test 2
... monoclonal antibody irreversibly crosslinked to protein G-agarose ... PDH complex from heart mitochondria. Also included ... for control immunocapture. ,The pyruvate dehydrogenase complex ... from small amounts of tissue. This facilitates ...
... innovative reagent for highly efficient transfer of ... cells. Unlike DNA transfection, with PULSin Protein ... timing of exogenous proteins in cells can ... be studied. Real time function blocking ...
... ST-195 allows real-time observations of cell cultures ... has 64 different strain parameters in addition ... thin silicon strain chamber used by the ... fluorescence microscopy. ST-195 can be used with ...
... demands on cell and tissue culture assumes ... Therefore, both cell concentration and percentage of ... precisely. The new Vi-CELLTM Cell Viability Analyzer ... to perform the trypan blue dye exclusion ...
Biology Products: